Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder

Status Completed

Clinical Trial Summary

Neurogenic bladder patients may have symptoms of urinary frequency, urgency, urgency incontinence and voiding symptoms due to bladder dysfunction arising from their underlying neurologic condition. Current treatment options are effective for some patients, however many patients are not optimally managed due to modest efficacy or significant side effects. Second line therapies include intravesical onabotulinum toxin, however it is associated with a risk of urinary retention, and patients with neurologic disorders often are unable to perform self catheterize due to physical limitations. Sacral neuromodulation is associated with an undesirably high cost and potential complications in this population. The use of transcutaneous tibial nerve stimulation is an alternative form of neuromodulation, and it may have some potential benefits over percutaneous tibial nerve stimulation. While some preliminary studies have suggested it may be effective, there are no high quality randomized trials. This proposal is a 3 month, randomized, sham-controlled, clinical trial to evaluate the short term clinical efficacy of at home transcutaneous tibial nerve stimulation. Valid and reliable patient reported outcome measures, and objective measures of incontinence have been included as outcomes.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Urinary Bladder, Neurogenic

Clinical Trial Details

NCT number	NCT02582151
Study type	Interventional
Source	Lawson Health Research Institute
Contact
Status	Completed
Phase	N/A
Start date	January 2016
Completion date	April 1, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05141487` - Feasibility of Triggered Sacral Neuromodulation for Neurogenic Bladder
Completed	`NCT01920243` - Evaluation of a Bowel and Bladder Health Management Program for Individuals With Spinal Cord Injury (SCI)	N/A
Completed	`NCT04528784` - Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis	N/A
Enrolling by invitation	`NCT03336424` - Urinary Disorders in Patients With Multiple Sclerosis: Invasive Vs Non-invasive Investigations.	N/A
Not yet recruiting	`NCT05075642` - Multicenter Observational Study for the Evaluation in Clinical Practice of Urinary Disorders in Multiple Sclerosis
Completed	`NCT02600715` - Reduction of Bladder Injection Pain With Belladonna Opiate Suppository	Phase 4
Recruiting	`NCT04128709` - Measurement of Bladder Pressure With a Novel External Device (Cystomanometer) - Home Use	N/A
Not yet recruiting	`NCT06336304` - NXT Post-Market Clinical Follow-up
Enrolling by invitation	`NCT05740527` - Ambulatory Closed-loop Stimulation for Bladder Control	N/A
Completed	`NCT02501928` - Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.	Phase 3
Recruiting	`NCT04819360` - Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Sclerosis	Phase 4
Terminated	`NCT02044510` - Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients	Phase 2/Phase 3
Completed	`NCT01557244` - A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition	Phase 3
Recruiting	`NCT05380661` - Heart Rate Variability and Anxiety During Urinary Bladder Catheterization	N/A
Recruiting	`NCT04193709` - Recovery of Bladder and Sexual Function After Human Spinal Cord Injury	N/A
Active, not recruiting	`NCT05232253` - Cystoealstometer (Bladder Monitor Device)-Home Use	N/A
Completed	`NCT03405285` - Connected Catheter Clinical Feasibility Study( CFS)	N/A
Completed	`NCT02673047` - Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder	N/A
Completed	`NCT01773213` - Detrusor Contraction During the Ice-water-test	N/A
Completed	`NCT01530620` - Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity	Phase 3